New lipid class may shed light on causes of dental disease
Myriad microbial species live in the mouth, and an imbalance in their relative numbers can lead to dental disease. In chronic adult periodontitis, a destructive inflammatory disease, researchers have found Porphyromonas gingivalis, of the Bacteroidetes phylum, in increased numbers between the tooth and gum.
Gingivitis precedes development of periodontitis, which occurs when the inflammatory lesion of gingivitis becomes destructive, resulting in bone loss and detachment. Researchers believe virulence factors of P. gingivalis contribute to this progression. These factors include lipopolysaccharide that may promote bone resorption, expression of hairlike fimbriae that may help bacteria attach to epithelial cells between tooth and gum, and proteolytic enzymes that may promote tissue degradation. These factors could work together to promote destruction of tissue surrounding a diseased tooth.
, a professor at the University of Connecticut School of Dental Medicine, described one of the possible mechanisms for delivering bacterial lipids to gingival tissues: “P. gingivalis can attach to the epithelium through its cell surface adhesion molecules, including fimbriae on the bacteria’s outer surface, and in so doing, it may deliver its cell wall lipids to epithelial cells through a process of lateral diffusion.”
In a in the Journal of Lipid Research, Nichols and colleagues describe isolating a new lipid class from lab-grown P. gingivalis using high-performance liquid chromatography, or HPLC, and mass spectrometry. “We noticed a small late-emerging lipid peak that eluted well after other lipid classes of P. gingivalis total lipids,” Nichols said.
The new lipid peak contained a group of related lipid species, with the most abundant having a negative ion mass of m/z 1256. The team had identified a new class of P. gingivalis lipid products — Lipid 1256. They later found that this lipid is elevated in diseased tissues and plaque samples from around teeth with periodontitis.
The Lipid 1256 class appears to be produced through a lipid synthetic pathway involving addition of amino acid or fatty acid components to the base glycine lipid structure, Lipid 342, with the final step being addition of diacylated phosphoglycerol to the serine dipeptide lipid class Lipid 654.
The researchers found that a neutralizing antibody blocked activation of human embryonic kidney cells transfected with human Toll-like receptor 2, or TLR2, demonstrating that Lipid 1256 engages TLR2. They also found that Lipid 1256 is a strong ligand for TLR2 when compared to the other serine/glycine lipid classes. Lipid 1256 stimulates release of two cytokines, IL-1β and TNF-α, from peripheral blood monocytes, both known to increase bone resorptive processes.
“Bacteria of the phylum Bacteroidetes are represented in large numbers in the gastrointestinal tract,” Nichols said, “so we wondered if Lipid 1256 is prevalent in those organisms.” They found that two common GI Bacteroidetes organisms produce Lipid 1256, suggesting they might affect chronic inflammatory disease of the GI tract by exposing the GI wall to these lipids.
Recovery of Lipid 1256 in the mouth and intestine means that both sources could contribute to diseases such as rheumatoid arthritis or atherosclerosis. Other researchers have found that these diseases may involve engagement of TLR2, which could occur if either the bacterial lipid or the bacteria enters the bloodstream. Future research evaluating the recovery of Lipid 1256 in human tissue samples may implicate lipids of the Bacteroidetes phylum in systemic diseases with a TLR2-dependent chronic inflammatory response.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.